Long-Acting Drug Delivery Strategies in Cancer Therapy
A special issue of Pharmaceutics (ISSN 1999-4923). This special issue belongs to the section "Drug Delivery and Controlled Release".
Deadline for manuscript submissions: closed (20 May 2023) | Viewed by 381
Special Issue Editor
2. Josep Carreras Leukaemia Research Institute, 08025 Barcelona, Spain
3. CIBER de Bioingeniería, Biomateriales y Nanomedicina, Instituto de Salud Carlos III, 28029 Madrid, Spain
4. Departament de Genètica i de Microbiologia, Universitat Autònoma de Barcelona, 08193 Bellaterra, Spain
Interests: nanomedicine; cancer therapy; protein materials; targeting; drug delivery systems; self-assembling
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
As cancer is the second leading cause of death worldwide, more efficient therapies are still needed. For this, many efforts are being made in order to improve the pharmacokinetics of administered drugs, as this is an effective way to enhance their therapeutic outcome. In this sense, current therapies are still mainly based on the intravenous administration of small molecules, which show a short biological half-life and, in consequence, require multiple doses. This administration pattern, far from being effective, generates large fluctuations in blood drug concentration and significantly increases the risk of potential side effects, strongly limiting these therapies’ use in clinical settings. Therefore, there is an urgent need to develop innovative long-acting drug delivery systems that allow the sustained release of the administered drug over a long period of time from several days to weeks. This approach not only significantly enhances the pharmacokinetics of the drug by keeping its level in the blood constant during the treatment, but also improves patients’ quality of life and increases their adherence to the therapy.
This Special Issue entitled “Long-Acting Drug Delivery Strategies in Cancer Therapy” seeks to collect current research progress in the development of therapeutic drug delivery systems that allow the sustained release of antitumoral drugs into the blood stream for improved pharmacokinetics and therapeutic efficiency. Therefore, this Special Issue invites all researchers working in this field to contribute with their original research articles, communications or reviews.
Dr. Ugutz Unzueta
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceutics is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- cancer therapy
- drug delivey system
- sustained release
- pharmacokinetics
- nanomedicine
